Smithkline Beecham Corporation

Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Astex Therapeutics Limited

Heather Hobbs

Gordon Saxty

John Liddle

Joanna Victoria Geden

Chuen Chan

Richard Peter Charles Cousins

Thomas Davis Roper, Iv

Hazel Joan Dyke

David E Bays

Panayiotis Alexandrou Procopiou

Paul Bamborough

Joelle Le

Suzanne Elaine Keeling

Brian Cox

Alison Judith Redgrave

Nigel James Parr

Timothy John Ritchie

Michael David Barker

Stephen Swanson

Jeremy John Payne

John Martin Pritchard

David George Allen

Simon Teanby Hodgson

Shiping Xie

Frank Ellis

Graham George Adam Inglis

Deborah Needham

Caroline Mary Cook

Caroline Whitworth

Sebastien Andre Campos

Gianpaolo Bravi

Michael David Woodrow

Paul Faulder

Simon Peace

Yannick Maurice Lacroix

Duncan Stuart Holmes

Christie Schulte

Simon Nicolle

Ashley Paul Hancock

Daniel J Price

Lee T Schaller

Andrew L Larkin

Dave Norman Deaton

Paul N Mortenson

Michael John Johnston

The invention relates to compounds of formula (I): wherein R, R, R, R, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.

Chemical compounds

Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.

Pyrazole derivatives used as CCR4 receptor antagonists

A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.

2-(purin-9-yl)-Tetrahydrofuran-3,4-diol derivatives

A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2 receptor are described.

2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives

There are provided according to the invention novel compounds of formula (I) wherein R , R , and R are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Growing community of inventors

Stevenage, United Kingdom

Heather Hobbs